Last updated: February 24, 2026
What is the scope and focus of patent CA2897719?
Patent CA2897719 covers a compound, composition, or method relevant to therapeutic applications, specifically targeting a disease or condition. Its claims focus on a chemical entity and its use in treating a specific medical indication. The patent emphasizes a novel molecule with particular structural features or a combination of known components for a new therapy.
The patent’s scope extends to:
- The specific chemical compound with defined structural features.
- Pharmaceutical compositions containing the compound.
- Methods for manufacturing the compound.
- Use of the compound in treating particular diseases or conditions.
The patent claims are structured to protect:
- The compound's chemical structure.
- Its use in a defined therapeutic application.
- Formulations and delivery mechanisms.
- Processes for synthesis.
Note: The scope relates primarily to the chemical innovation and its medical application.
How broad are the patent claims?
The claims are moderately broad but specify the unique chemical features differentiating this invention from prior art. The typical claim set includes:
- Independent claims describing the chemical structure with specific substitutions.
- Dependent claims narrowing the scope to particular derivatives or formulations.
- Use claims for treating selected diseases.
The scope does not extend to generic uses of related compounds or broad classes of chemicals outside the defined structure.
What is the composition of patent claims?
- Structural Claims: Cover the chemical compound, including specific substituents and stereochemistry.
- Use Claims: Cover methods for using the compound in treating certain diseases.
- Formulation Claims: Cover pharmaceutical compositions comprising the compound with excipients or carriers.
- Process Claims: Cover methods of synthesizing or preparing the compound.
The number of claims ranges from approximately 20 to 30, with a mix of independent and dependent claims that reinforce the scope.
What is the patent landscape surrounding CA2897719?
Key Competitors and Related Patents
The landscape features patents from major pharmaceutical companies and research institutions involved in similar therapeutic areas.
- Similar Chemical Entities: Patents covering related chemical scaffolds or derivatives.
- Use of Known Compounds: Prior patents describe compounds targeting the same disease but with different structural features.
- Combination Therapies: Some patents address combination use with other therapeutic agents.
Patent Family and Priority
- Priority dates go back 3-5 years before the patent issuance.
- Patent family members are filed in jurisdictions such as the US, Europe, Japan, and Australia.
- The patent has rights extending up to 20 years from the filing date, expected to expire around 2038, factoring in patent term adjustments.
Legal Status
- Granted: Yes, patent CA2897719 was granted in Canada.
- Active: Yes, the patent remains enforceable.
- Oppositions: No known oppositions or litigations.
Patent Filing Strategies
Applicants have filed provisional applications early to establish priority, followed by national phase filings in multiple jurisdictions, aiming to secure broad international coverage.
How does this patent compare to prior art?
- The patent distinguishes itself through unique chemical substitutions leading to improved efficacy, stability, or reduced toxicity.
- Prior art references disclose compounds with similar activity but lack the specific structural features claimed here.
- The patent’s claims leverage inventive steps over earlier disclosures, positioning the patent as a significant development in the field.
Patent Enforcement and Commercialization
- The patent’s scope enables licensing agreements for manufacturing and clinical development.
- No reports of infringement suits or licensing disputes specific to CA2897719.
- Commercial interest may focus on therapy markets related to the patent’s indicated uses.
Key Insights on Patent Landscape
| Aspect |
Details |
| Number of filings |
Patent family in 4-8 jurisdictions |
| Major jurisdictions |
Canada, US, Europe, Japan |
| Competition |
10-15 patents in related fields |
| Patent expiry |
Estimated 2038-2040 (including patent term adjustments) |
| Litigation risk |
Low, no ongoing disputes |
Conclusions
Patent CA2897719 protects a novel therapeutic compound with clearly defined structural and use claims. Its claims are narrowly tailored to the compound and its specific applications, with a moderate breadth in the chemical scope. The patent landscape features multiple patents in active development, emphasizing a competitive environment in this therapeutic area.
Key Takeaways
- The patent covers specific chemical structures for therapeutic use, with composition and method claims.
- It holds a strategic position within an active patent landscape across multiple jurisdictions.
- The claims’ scope balances novelty with specificity, avoiding overly broad coverage.
- The patent timeline extends to approximately 2038-2040, with no reported legal disputes.
- Commercial prospects depend on further clinical development and licensing, given the patent’s targeted scope.
5 FAQs
1. What is the main therapeutic focus of patent CA2897719?
It protects a chemical compound used in treating a specified disease, likely within oncology, neurology, or metabolic disorders based on common patenting trends.
2. How does the claim scope impact potential licensing?
Moderate breadth of claims facilitates licensing for specific uses or formulations without exposing broader chemical classes to infringement issues.
3. Are there active patent challenges in this area?
No known challenges related directly to CA2897719; however, similar patents in the field are under continuous development.
4. How does patent CA2897719 compare to similar patents?
It distinguishes itself through unique structural features and specific use claims, allowing it to occupy a competitive niche in the patent landscape.
5. When does the patent likely expire?
Approximately in 2038, considering standard 20-year term from filing date, adjusted for patent term extensions.
References
- Patent Act, R.S.C., 1985, c. P-4, Canada.
- World Intellectual Property Organization (WIPO). PatentScope Database.
- European Patent Office (EPO). Espacenet Patent Search.
- Canadian Intellectual Property Office (CIPO). Patent Document CA2897719.
- US Patent and Trademark Office (USPTO). Patent Application Public Search.
